17.5 MEUR blended funding from EIC
PharmNovo is very pleased to announce that we have been awarded a 2.5 MEUR grant and an opportunity for up to 15m EUR equity investment from the European Innovation Council (EIC) for innovative pain treatment. The equity part being contingent on investments of equal amounts from co-investors.
From a total number of 969 companies that submitted a full proposal, 347 companies were interviewed by juries of experienced investors and entrepreneurs. We are among the 68 startups selected out of 969 applicants, judged on the criteria of excellence, impact and risk level.
This funding will support PharmNovo to advance PN6047 through a Phase IIa proof of concept (PoC) study. Demonstrating efficacy in this study would represent a major advance in neuropathic pain treatment, positioning PN6047 as the first-in-class drug in a new category of pain relief medications—delta opioid-biased receptor agonists (DOBRAs).
The lead drug candidate from PharmNovo, PN6047, offers a novel approach for treating neuropathic pain. Unlike conventional opioid drugs, PN6047 is a highly selective delta opioid receptor agonist (DORA) with a unique molecular structure that activates the G protein signaling pathway while avoiding unwanted side effects such as analgesic tolerance and proconvulsant activity.
The support from Horizon Europe will be crucial in advancing our clinical trials and bringing this much-needed pain relief solution to patients.
17.5 MEUR blended funding from EIC
PharmNovo is very pleased to announce that we have been awarded a 2.5 MEUR grant and an opportunity for up to 15m EUR equity investment from the European Innovation Council (EIC) for innovative pain treatment. The equity part being contingent on investments of equal amounts from co-investors.
From a total number of 969 companies that submitted a full proposal, 347 companies were interviewed by juries of experienced investors and entrepreneurs. We are among the 68 startups selected out of 969 applicants, judged on the criteria of excellence, impact and risk level.
This funding will support PharmNovo to advance PN6047 through a Phase IIa proof of concept (PoC) study. Demonstrating efficacy in this study would represent a major advance in neuropathic pain treatment, positioning PN6047 as the first-in-class drug in a new category of pain relief medications—delta opioid-biased receptor agonists (DOBRAs).
The lead drug candidate from PharmNovo, PN6047, offers a novel approach for treating neuropathic pain. Unlike conventional opioid drugs, PN6047 is a highly selective delta opioid receptor agonist (DORA) with a unique molecular structure that activates the G protein signaling pathway while avoiding unwanted side effects such as analgesic tolerance and proconvulsant activity.
The support from Horizon Europe will be crucial in advancing our clinical trials and bringing this much-needed pain relief solution to patients.
Latest news
View all
Watch PharmNovo at LSX in Lisbon
Take the opportunity to listen to Per von Mentzer, CEO, presenting PN6047 at the LSX World Europe congress in Lisbon, March 2026. Learn how PharmNovo is shaping a new approach to pain relief with the goal to prove that powerful pain treatment doesn’t have to come with the cost of addiction. Discover how the company’s lead candidate PN6047, delivers effective pain relief without activating the mu-opioid receptor and avoiding the addiction risks associated with conventional opioids. The Phase II-ready Delta Opioid Receptor Agonist (DORA) with first-in-class potential, PN6047 represents a safer, non-addictive approach targeting a neuropathic pain market that is expected to double until 2033 and reach 13 bEUR.
Read more
Capsules ready for Phase IIa Study
PharmNovo is pleased to announce that that the company has completed drug product manufacturing for its lead candidate PN6047. This is an important milestone as the company prepares for its upcoming Phase IIa proof-of-concept study in neuropathic pain.
Read more
Welcome on Board
As the company prepares for the next phase of clinical development, the new Board composition strengthens our strategic capabilities ahead of Phase II development of our lead candidate, PN6047.
Read more
